Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Steve Nicholls Articles

PlayHuygens: Does PCSK9 inhibition impact the vulnerable plaque?

Huygens: Does PCSK9 inhibition impact the vulnerable plaque?

The HUYGENS study (High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study NCT03570697) investigated the impact of PCSK9 inhibition on the vulnerable plaque. Results were reported at ESC Congress 2021 (Virtual). Professor Stephen Nicholls, Monash University, Melbourne, Australia discusses the background to the…

read more »
PlayVIDEO: Prof Steve Nicholls discusses STRENGTH

VIDEO: Prof Steve Nicholls discusses STRENGTH

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) puts the STRENGTH results in context

read more »
PlayVIDEO: Prof Steve Nicholls fish oils and AF

VIDEO: Prof Steve Nicholls fish oils and AF

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) discusses fish oils and risk for atrial fibrillation and implications for clinical practice

read more »
Targeting PCSK9 inhibitors to the right patient

Targeting PCSK9 inhibitors to the right patient

Professor Stephen J Nicholls MBBS PhD, Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia  The clinical development of pharmacological inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) has received considerable attention by virtue of the expectation that these treatments would have the potential to…

read more »
Current status of IVUS studies of plaque burden: what next with GLAGOV?

Current status of IVUS studies of plaque burden: what next with GLAGOV?

Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…

read more »
PlayESC Congress 2015 buzz: Novel LDL lowering treatments

ESC Congress 2015 buzz: Novel LDL lowering treatments

Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the PCSK9 inhibitors versus CETP inhibitors

read more »
PlayPCSK9 therapeutics – the next story?

PCSK9 therapeutics – the next story?

Results from a Phase I trial of a new approach to PCSK9 therapeutics, small interfering RNA (siRNA) were presented at ESC Congress 2015. Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the findings and potential clinical implications of this strategy: what would be the…

read more »
PlayHow will PCSK9 inhibitors be used in practice?

How will PCSK9 inhibitors be used in practice?

Professor Steven Nicholls, Professor of Cardiology at the University of Adelaide and the inaugural SAHMRI Heart Foundation Heart Health Theme Leader at the South Australian Health and Medical Research Institute, Australia, discusses the patients in whom these new treatments will be used initially and speculates…

read more »
PlayDoes PCSK9 inhibition impact atherosclerosis?

Does PCSK9 inhibition impact atherosclerosis?

Research shows that progression of atherosclerosis – narrowing of the coronaries due to high density lipoprotein cholesterol (HDL-C) – may be reduced if statins are combined with new PCSK9 inhibitors. This could prevent heart attacks according to one of the trialists, Professor Steve Nicholls from…

read more »